Vanda Pharmaceuticals hires European General Manager

Gian Piero Reverberi has more than 20 years of pharma industry experience

Vanda Pharmaceuticals, a US biopharmaceutical company developing drugs for central nervous system disorders, has named Gian Piero Reverberi as Senior Vice President, European General Manager.

Reverberi has more than 20 years of experience in the pharmaceutical industry, holding senior management and regional leadership positions over the last 10 years.

Prior to joining Vanda, Reverberi acted as a corporate advisor supporting several companies in the development of their commercial and geographical expansion strategies. He was Senior Vice President, International Specialty Pharma at Shire Pharmaceuticals, with responsibility for Shire's speciality pharma business in EMEA, Canada, Australia, Japan, Asia Pacific and Latin America. Prior to this position, he was General Manager, Italy at Shire.

Before joining Shire, Reverberi spent 10 years with Eli Lilly in Italy and the US where he held several commercial positions.

You may also like

Packaging

Innovating primary packaging for parenteral drugs: challenges and future directions

The new challenges brought about by the pandemic call for an increasingly scientific approach to the evolution of single packaging elements in order to anticipate the needs of new drug formulations and guarantee a more enhanced, measurable and stable level of performance
Regulatory

US Pharmacopeia details mass spectrometry guidelines to advance biologics impurity control

The new chapter aims to standardise the use of mass spectrometry-based analysis in the biopharmaceutical industry, which can be used to detect impurities in cell and gene therapies, antibodies and other biologics
Packaging

How pharma packaging manufacturers role is evolving: the case of extractables testing

As the pharmaceutical industry continues to grow and evolve, extractables testing is a critical component of the pharmaceutical industry's efforts to prioritise quality and safety, ensuring one of the key functions pharma containers are designed for, says Anna Malori, Head of Product Management at Bormioli Pharma
Regulatory

Merck's Welireg approved for cancers associated with von Hippel-Lindau disease in China

The once-daily drug is the first HIF-2α to be approved in China, exhibiting a 49% objective response rate (ORR)
Manufacturing

Aurobindo Pharma signs $25m respiratory drug development and commercialisation deal with global pharma company

The companies will co-develop and commercialise respiratory therapeutics, diversifying Aurobindo's current portfolio
Packaging

Dual-chamber packaging systems as a simplification factor in the supply chain

Dual-chamber packaging solutions could represent a new frontier also to package parenteral drugs, simplifying the supply chain through reconstitution, potentially making logistics more flexible and efficient, says Cecilia Bassi, Product Manager at Bormioli Pharma
Regulatory

Pfizer gains European Commission approval for haemophilia A and B drug, Hympavzi

The subcutaneous therapeutic is the first and only anti-tissue factor pathway inhibitor approved for the treatment of haemophilia A or B, and is available in an auto-injector format
Subscribe now